Abstract:
Surgical resection is recommended for advanced-stage, resectable glottic cancer. However, total laryngectomy results in the loss of vocal function and reduces patients\' quality of life. At our institution, patients with cT3N0M0 stage III resectable glottic cancer who wish to preserve their larynx are treated with super-selective cisplatin infusion with concomitant radiotherapy (RADPLAT) to improve local control over systemic chemotherapy. Herein, we present 4 patients with glottic cancer who underwent biweekly intra-arterial infusion chemotherapy combined with radiation therapy 3 times. For intra-arterial infusion chemotherapy, 100 mg cis-diaminodichloroplatinum was infused into the superior thyroid artery, including the superior laryngeal artery branch. Thereafter, intensity-modulated radiation therapy was administered at doses of 70 Gy in 35 fractions for 3 patients and 66 Gy in 33 fractions for 1 patient. These patients showed complete response after chemoradiotherapy with no recurrence or metastases during the follow-up period to date (mean follow-up period: 56 months, range: 39-76 months).
摘要:
晚期推荐手术切除,可切除的声门癌。然而,全喉切除术导致声带功能丧失,降低患者生活质量.在我们的机构,希望保留喉的cT3N0M0III期可切除声门癌患者接受超选择性顺铂输注联合放疗(RADPLAT)治疗,以改善全身化疗的局部控制.在这里,我们介绍了4例声门型喉癌患者,他们每两周接受一次动脉内灌注化疗联合放疗3次.对于动脉内灌注化疗,向甲状腺上动脉注入100毫克顺式二氨基二氯铂,包括喉上动脉分支.此后,3例患者的调强放疗剂量为70Gy,分为35个部分;1例患者的调强放疗剂量为66Gy,分为33个部分.这些患者在放化疗后表现出完全缓解,在迄今为止的随访期间没有复发或转移(平均随访期:56个月,范围:39-76个月)。